+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Histotripsy for Non-Invasive Ablation of Hepatocellular Carcinoma (HCC) Tumor in a Subcutaneous Xenograft Murine Model



Histotripsy for Non-Invasive Ablation of Hepatocellular Carcinoma (HCC) Tumor in a Subcutaneous Xenograft Murine Model



Conference Proceedings 2018: 6064-6067



Histotripsy fractionates tissue through a mechanical, non-invasive ultrasonic ablation process that precisely controls acoustic cavitation while utilizing real-time ultrasound (US) imaging guidance. This study investigates the potential, feasibility and tumor volume reduction effects of histotripsy for liver cancer ablation in a subcutaneous in vivo murine Hepatocellular Carcinoma (HCC) model. Hep3B tumors were generated in the right flanks of 14 NSG and 7 NOD-SCID mice. The mice were grouped as follows: A (acute, NSG with n=9 treatment and n=1 control), B (chronic, NSG with n=2 treatment and n=2 control) and C (chronic NODSCID, with n=6 treatment and n=1 control). Treatment was performed when the tumor diameters reached >5 mm. 1-2 cycle histotripsy pulses at 100 Hz PRF (p- >30 MPa) were delivered using a custom built 1 MHz therapy transducer attached to a motorized positioner, which scanned the transducer focus to traverse the targeted tumor volume, guided by real-time US imaging. Tumor ablation effectiveness was assessed by obtaining T1, T2 and T2* weighted MR images. Post euthanasia, treated tumor, brain, and lung tissue samples were harvested for histology. Histology of acute group A showed fractionation of targeted region with a sharp boundary separating it from untreated tissue. Groups B and C demonstrated effective tumor volume reduction post treatment on MRI as the homogenate and edema were resorbed within 23 weeks. However, as the tumor was subcutaneous, it was not possible to set adequate treatment margin and since the mice were immune-compromised, residual viable tumor cells eventually developed into tumor regrowth at 3-9 weeks after histotripsy. Groups B and C showed no signs of metastasis in the lung and brain. Our study successfully demonstrated the potential of histotripsy for non-invasive HCC ablation in a subcutaneous murine model. Additional work is ongoing to study the response of histotripsy in immune-competent orthotopic liver tumor models.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065804101

Download citation: RISBibTeXText

PMID: 30441719

DOI: 10.1109/embc.2018.8513650


Related references

Non-Invasive Ultrasound Liver Ablation Using Histotripsy: Chronic Study in an In Vivo Rodent Model. Ultrasound in Medicine and Biology 42(8): 1890-1902, 2016

Non-Invasive Liver Ablation Using Histotripsy: Preclinical Safety Study in an In Vivo Porcine Model. Ultrasound in Medicine and Biology 43(6): 1237-1251, 2017

Histotripsy: minimally invasive technology for prostatic tissue ablation in an in vivo canine model. Urology 72(3): 682-686, 2008

P0225 : Combination of Cd40L co-stimulation with alpha-fetoprotein pulsed dendritic cells induced an early and strong Th1-shift in the tumor environment and synergistic antitumoral effects in subcutaneous and orthotopic murine hepatocellular carcinoma model. Journal of Hepatology 62: S391-S392, 2015

Characterization and Validation of Hepatocellular Carcinoma (HCC) Xenograft tumor as a Suitable Liver Cancer Model for. Asian Pacific Journal of Cancer Prevention 19(6): 1627-1631, 2018

Developmental impact and lesion maturation of histotripsy-mediated non-invasive tissue ablation in a fetal sheep model. Ultrasound in Medicine and Biology 39(6): 1047-1055, 2013

Image-guided non-invasive ultrasound liver ablation using histotripsy: feasibility study in an in vivo porcine model. Ultrasound in Medicine and Biology 39(8): 1398-1409, 2013

Mp100-02 Boiling Histotripsy Ablation Of Renal Carcinoma In A Chronic Rat Model. The Journal of Urology 197(4): e1329-e1330, 2017

Activated human hepatic stellate cells promote growth of human hepatocellular carcinoma in a subcutaneous xenograft nude mouse model. Cell Biochemistry and Biophysics 70(1): 337-347, 2014

Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model. Journal of Urology 188(5): 1957-1964, 2012

Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 18(12): 900-904, 2010

Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma. Ajr. American Journal of Roentgenology 202(6): W559-W566, 2014

Yttrium-90-Labeled Anti-Glypican-3 Antibody Reduces Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. Gastroenterology 152(5): S1236-S1237, 2017

Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma. Biomedical Journal 39(6): 400-406, 2016

Berberine inhibits human tongue squamous carcinoma cancer tumor growth in a murine xenograft model. Phytomedicine 16(9): 887-890, 2009